Toward development of a precision medicine framework for metastatic, castration-resistant
prostate cancer (mCRPC), we established a multi-institutional clinical sequencing …

We systematically generated large-scale data sets to improve genome annotation for the
nematode Caenorhabditis elegans, a key model organism. These data sets include …

Prostate cancer is the second most common cause of male cancer deaths in the United
States. However, the full range of prostate cancer genomic alterations is incompletely …

The lack of in vitro prostate cancer models that recapitulate the diversity of human prostate
cancer has hampered progress in understanding disease pathogenesis and therapy response…

An increasingly recognized resistance mechanism to androgen receptor (AR)-directed therapy
in prostate cancer involves epithelial plasticity, in which tumor cells demonstrate low to …

The analysis of exonic DNA from prostate cancers has identified recurrently mutated genes,
but the spectrum of genome-wide alterations has not been profiled extensively in this …

Heterogeneity in the genomic landscape of metastatic prostate cancer has become apparent
through several comprehensive profiling efforts, but little is known about the impact of this …

Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of prostate cancer that
most commonly evolves from preexisting prostate adenocarcinoma (PCA). Using next-…

Precision medicine is an approach that takes into account the influence of individuals' genes,
environment, and lifestyle exposures to tailor interventions. Here, we describe the …

Comprehensive genomic characterization of prostate cancer has identified recurrent alterations
in genes involved in androgen signaling, DNA repair, and PI3K signaling, among others. …